ENTA is basing its royalty guidance for the next two quarters (#msg-142751191) on $3.6B of 2018 Mavyret sales, since ABBV recently raised its guidance from $3.5B to more than $3.5B.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”